Rapamycin inhibits ox-LDL-induced inflammation in human endothelial cells in vitro by inhibiting the mTORC2/PKC/c-Fos pathway

被引:0
作者
Juan-juan Sun
Xiao-wei Yin
Hui-hui Liu
Wen-xiu Du
Lu-yao Shi
Ya-bo Huang
Fen Wang
Chun-feng Liu
Yong-jun Cao
Yan-lin Zhang
机构
[1] Second Affiliated Hospital of Soochow University,Department of Neurology
[2] First Affiliated Hospital of Soochow University,Department of Neurosurgery
[3] Jiangsu Key Laboratory of Translational Research and Therapy for Neuro-Psycho-Diseases and Institute of Neuroscience,Department of Neurology
[4] Soochow University,undefined
[5] First Hospital of Handan City,undefined
来源
Acta Pharmacologica Sinica | 2018年 / 39卷
关键词
atherosclerosis; rapamycin; endothelial cells; ox-LDL; ICAM-1; E-selectin; mTORC2; PKC; c-Fos; HUVECs;
D O I
暂无
中图分类号
学科分类号
摘要
Rapamycin and its derivative possess anti-atherosclerosis activity, but its effects on adhesion molecule expression and macrophage adhesion to endothelial cells during atherosclerosis remain unclear. In this study we explored the effects of rapamycin on ox-LDL-induced adhesion molecule expression and macrophage adhesion to endothelial cells in vitro and the underlying mechanisms. Ox-LDL (6–48 μg/mL) dose-dependently increased the protein levels of two adhesion molecules, intercellular adhesion molecule-1 (ICAM-1) and E-selectin, in human umbilical vein endothelial cells (HUVECs), whereas pretreatment with rapamycin (1–10 μmol/L) dose-dependently inhibited ox-LDL-induced increase in the adhesion molecule expression and macrophage adhesion to endothelial cells. Knockdown of mTOR or rictor, rather than raptor, mimicked the effects of rapamycin. Ox-LDL (100 μg/mL) time-dependently increased PKC phosphorylation in HUVECs, which was abolished by rapamycin or rictor siRNA. Pretreatment with PKC inhibitor staurosporine significantly reduced ox-LDL-stimulated adhesion molecule expression and macrophage adhesion to endothelial cells, whereas pretreatment with PKC activator PMA/TPA attenuated the inhibitory effect of rapamycin on adhesion molecule expression. Ox-LDL (100 μg/mL) time-dependently increased c-Fos levels in HUVECs, and pretreatment with rapamycin or rictor siRNA significantly decreased expression of c-Fos. Knockdown of c-Fos antagonized ox-LDL-induced adhesion molecule expression and macrophage adhesion to endothelial cells. Our results demonstrate that rapamycin reduces ox-LDL-stimulated adhesion molecule expression and macrophage adhesion to endothelial cells by inhibiting mTORC2, but not mTORC1, and mTORC2 acts through the PKC/c-Fos signaling pathway.
引用
收藏
页码:336 / 344
页数:8
相关论文
共 224 条
[11]  
Suganuma I(2004)Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the oral sirolimus to inhibit recurrent in-stent stenosis (OSIRIS) trial Circulation 110 790-5
[12]  
Tanaka Y(1994)Rapamycin: a novel immunosuppressive macrolide Med Res Rev 14 1-22
[13]  
Sasaki A(2012)mTOR signaling in growth control and disease Cell 149 274-93
[14]  
Takahashi Y(2002)Two mTOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control Mol Cell 10 457-68
[15]  
Zhu H(2002)mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery Cell 110 163-75
[16]  
Yoshimoto T(2002)Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action Cell 110 177-89
[17]  
Guo YL(2007)Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40 Nat Cell Biol 9 316-23
[18]  
Bai R(2007)PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase Mol Cell 25 903-15
[19]  
Chen CX(2003)GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR Mol Cell 11 895-904
[20]  
Liu DQ(2004)Rictor, a novel binding partner of mTOR, defies a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton Curr Biol 14 1296-302